Tryptyr Dosage: One Drop in Each Eye Twice Daily
The FDA-approved Tryptyr regimen is one drop in each eye twice daily, about 12 hours apart. Single-dose vials are discarded after use, contact lenses are removed before dosing, and other eye drops are separated by at least five minutes.
Timeline
- 2025-05-28: FDA approved Tryptyr for the signs and symptoms of dry eye disease.
- Each prescribed dose: Use one single-dose vial for both eyes, discard the remainder and separate other eye medicines by at least five minutes.
The FDA-approved dose of Tryptyr, the brand name for acoltremon ophthalmic solution 0.003%, is one drop in each eye twice daily, approximately 12 hours apart. It is a prescription eye drop indicated for the signs and symptoms of dry eye disease. The label’s wording describes the standard regimen; a patient should follow the instructions from the prescribing clinician and should not increase the number of drops or frequency based only on an online summary. [1][2][3]
Tryptyr comes in preservative-free single-dose vials. The label instructs users to wash their hands, open a vial immediately before dosing, use that vial for both eyes and discard it with any liquid left over. The vial should not be saved for another dose. Its tip should not touch the eye, fingers or another surface because contact could cause eye injury or contaminate the solution. The FDA-approved instructions for use show the handling sequence in detail. [1][2]
Contact lenses must be removed before Tryptyr is instilled and may be put back 15 minutes afterward. When another topical eye medicine is also used, the products should be administered at least five minutes apart. If a dose is missed, the label says to continue with the next dose rather than giving an extra dose. Questions about the order of several prescribed eye products should go to the prescriber or pharmacist. [1]
FDA approved Tryptyr on May 28, 2025 after evaluating efficacy in two randomized, double-masked, vehicle-controlled Phase 3 studies called COMET-2 and COMET-3. Together they enrolled 931 people with dry eye disease at 46 U.S. sites. Participants were at least 30 years old, had a history of artificial-tear use and completed a vehicle run-in before randomization. Additional studies contributed to the agency’s safety evaluation. [2][3]
The primary trial measure was the proportion of participants whose unanesthetized Schirmer tear score increased by at least 10 millimeters at day 14. Both trials showed a statistically significant advantage over vehicle for that measure; the treatment differences were 34.4 and 38.8 percentage points. The label says consistent results were observed through day 90. This endpoint measures tear production and does not guarantee that every patient will feel the same amount of symptom relief. [1][2]
Burning or stinging when the drop was placed in the eye was the most common adverse reaction. The FDA label reports instillation-site pain in about 50 percent of treated patients in the controlled trials, although fewer than 1 percent stopped treatment because of it. Trial percentages describe groups and cannot predict an individual response. New, severe, persistent or concerning eye symptoms warrant prompt advice from the prescribing clinician rather than self-adjusting the regimen. [1][2]
Storage instructions matter because the packaging is designed around unopened foil pouches and disposable vials. Patients should read the current carton and FDA-approved instructions each time they receive the medicine, since labeling can be revised. This guide explains the approved regimen but does not determine whether Tryptyr is suitable for a particular person, whether symptoms are caused by dry eye, or how it should fit with other treatment. Those decisions belong with an eye-care professional who knows the patient’s history. [1][2]
Sources
- FDA — Tryptyr prescribing information and instructions for use
- FDA — Drug Trials Snapshot: Tryptyr
- FDA — Tryptyr approval letter